Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label study of edoxaban after femoropopliteal endovascular intervention in peripheral arterial disease
2012-003009-88Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of edoxaban in arteriosclerosis obliterans (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Clinically relevant bleeding. Started Nov 2012; status: completed.
02
Drugs
edoxaban
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2012-003009-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003009-88.